A multi-center, open-label, randomized study of the pharmacokinetics of azithromycin versus moxifloxacin in conjunctiva and aqueous humor following single or multiple ocular administration of Azasite [azithromycin] ophthalmic solution, 1 percent or Vigamox [moxifloxacin] in subjects undergoing routine cataract surgery.

Trial Profile

A multi-center, open-label, randomized study of the pharmacokinetics of azithromycin versus moxifloxacin in conjunctiva and aqueous humor following single or multiple ocular administration of Azasite [azithromycin] ophthalmic solution, 1 percent or Vigamox [moxifloxacin] in subjects undergoing routine cataract surgery.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2011

At a glance

  • Drugs Azithromycin; Moxifloxacin
  • Indications Bacterial infections; Ophthalmic infections
  • Focus Pharmacokinetics
  • Sponsors Inspire Pharmaceuticals
  • Most Recent Events

    • 27 Apr 2010 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Company added (Merck and Co) as reported by ClinicalTrials.gov.
    • 18 Sep 2009 Actual number of patients (116) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top